Therapeutic implication of mTORC2 in oral squamous cell carcinoma

Oral squamous cell carcinoma (OSCC) represents 2–3% of all human cancers and is the 6th most frequent cancer in the world [1,2]. OSCC has continually shown a poor prognosis and remains a lethal disease for >50% of cases diagnosed annually [3]. The current management and treatment of OSCC for most patients is surgery, and postoperative concurrent chemoradiotherapy is a widely accepted standard of care for high-risk OSCC [4]. Recently, Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, was approved for the treatment of locally advanced (LA) and recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in December 2012 in Japan.

http://ift.tt/2ib2gD3